Warfarin Resistance: A Case Report

dc.authoridGonlugur, Ugur/0000-0001-8720-2788
dc.authoridSılan, Fatma/0000-0001-7191-2240
dc.contributor.authorGonlugur, Ugur
dc.contributor.authorGonlugur, Tanseli
dc.contributor.authorÖzdemir, Öztürk
dc.contributor.authorSılan, Fatma
dc.date.accessioned2025-01-27T20:26:53Z
dc.date.available2025-01-27T20:26:53Z
dc.date.issued2019
dc.departmentÇanakkale Onsekiz Mart Üniversitesi
dc.description.abstractWarfarin is the most widely prescribed anticoagulant in the world. Patients who need more than 15 mg per day should be considered warfarin-resistant. Nearly 30 genes have been reported in association with warfarin pharmacogenetics but genetic polymorphisms in the genes encoding CYP2C9 and VKORC1 have been shown to act as the most important determinants of drug dosage requirements. The major enzyme responsible for the metabolism of S-warfarin, the more potent of warfarin's two stereoisomers, is CYP2C9. Warfarin inhibits vitamin K epoxide reductase (VKOR). A 30-year-old woman was referred to our clinic for pulmonary embolism. She was treated with low molecular weight heparin. The warfarin dose was titrated up to 15 mg daily but after one week, the INR (international normalized ratio) was still subtherapeutic level at 1.8. In this paper, we discuss underlying genetic polymorphisms about warfarin resistance.
dc.identifier.doi10.4274/eajem.galenos.2018.41033
dc.identifier.endpage63
dc.identifier.issn2149-5807
dc.identifier.issn2149-6048
dc.identifier.issue1
dc.identifier.startpage61
dc.identifier.trdizinid307646
dc.identifier.urihttps://doi.org/10.4274/eajem.galenos.2018.41033
dc.identifier.urihttps://search.trdizin.gov.tr/tr/yayin/detay/307646
dc.identifier.urihttps://hdl.handle.net/20.500.12428/22486
dc.identifier.volume18
dc.identifier.wosWOS:000489680800013
dc.identifier.wosqualityN/A
dc.indekslendigikaynakWeb of Science
dc.indekslendigikaynakTR-Dizin
dc.language.isoen
dc.publisherEmergency Medicine Physicians Assoc Turkey
dc.relation.ispartofEurasian Journal of Emergency Medicine
dc.relation.publicationcategoryinfo:eu-repo/semantics/openAccess
dc.rightsinfo:eu-repo/semantics/openAccess
dc.snmzKA_WoS_20250125
dc.subjectWarfarin
dc.subjectvitamin K epoxide reductases
dc.subjectVKORC1
dc.titleWarfarin Resistance: A Case Report
dc.typeArticle

Dosyalar